Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dexlansoprazole in Healthy Chinese Subjects
NCT03316976Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration at Day 1 and 1 more. Started Nov 2017; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03316976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316976.